Jessica L Dodge, MD | |
24 Hospital Ave, Department Of Pathology, Danbury, CT 06810-6099 | |
(203) 739-7034 | |
Not Available |
Full Name | Jessica L Dodge |
---|---|
Gender | Female |
Speciality | Pathology |
Experience | 28 Years |
Location | 24 Hospital Ave, Danbury, Connecticut |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134176522 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 218973 (Massachusetts) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Saint Mary's Hospital | Waterbury, CT | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Saint Francis Care Medical Group Pc | 3274436845 | 20 |
News Archive
Infections with bacterium Clostridium difficile have rapidly become a significant medical problem in hospitals and long-term care facilities. The bacteria cause diarrhea and life-threatening inflammation of the colon by producing toxins that kill the endothelial cells that form the lining of the gut.
Amarin Corporation plc today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital. The new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavistock Life Sciences Company and RA Capital. Cowen and Company, LLC acted as the exclusive placement agent for the transaction.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.
A new study has found that programs aimed at helping people prevent or manage diabetes are most successful if they are directed at the patient or the health care system. Programs aimed at physicians were only successful for patients with poorer diabetes control.
Shire plc today announced that it has received further guidance from the U.S. Food and Drug Administration on the regulatory path for SHP 465 (triple-bead mixed amphetamine salts MAS), an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults.
› Verified 7 days ago
Entity Name | Saint Francis Care Medical Group Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1760690101 PECOS PAC ID: 3274436845 Enrollment ID: O20040130000318 |
News Archive
Infections with bacterium Clostridium difficile have rapidly become a significant medical problem in hospitals and long-term care facilities. The bacteria cause diarrhea and life-threatening inflammation of the colon by producing toxins that kill the endothelial cells that form the lining of the gut.
Amarin Corporation plc today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital. The new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavistock Life Sciences Company and RA Capital. Cowen and Company, LLC acted as the exclusive placement agent for the transaction.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.
A new study has found that programs aimed at helping people prevent or manage diabetes are most successful if they are directed at the patient or the health care system. Programs aimed at physicians were only successful for patients with poorer diabetes control.
Shire plc today announced that it has received further guidance from the U.S. Food and Drug Administration on the regulatory path for SHP 465 (triple-bead mixed amphetamine salts MAS), an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Jessica L Dodge, MD 24 Hospital Ave, Department Of Pathology, Danbury, CT 06810-6099 Ph: (203) 739-7034 | Jessica L Dodge, MD 24 Hospital Ave, Department Of Pathology, Danbury, CT 06810-6099 Ph: (203) 739-7034 |
News Archive
Infections with bacterium Clostridium difficile have rapidly become a significant medical problem in hospitals and long-term care facilities. The bacteria cause diarrhea and life-threatening inflammation of the colon by producing toxins that kill the endothelial cells that form the lining of the gut.
Amarin Corporation plc today announced it has closed its $70 million private placement. The transaction was led by existing investor, Fountain Healthcare Partners, on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital. The new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavistock Life Sciences Company and RA Capital. Cowen and Company, LLC acted as the exclusive placement agent for the transaction.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.
A new study has found that programs aimed at helping people prevent or manage diabetes are most successful if they are directed at the patient or the health care system. Programs aimed at physicians were only successful for patients with poorer diabetes control.
Shire plc today announced that it has received further guidance from the U.S. Food and Drug Administration on the regulatory path for SHP 465 (triple-bead mixed amphetamine salts MAS), an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults.
› Verified 7 days ago
Samuel P Barasch, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-739-7453 | |
Marcelo Ferreira Cassini, M.D., PH.D. Pathology Medicare: Medicare Enrolled Practice Location: 24 Hospital Ave Dept Of, Danbury, CT 06810 Phone: 203-739-7034 | |
Hani El Fanek, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7306 | |
Ramapriya Vidhun, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7306 | |
Mary S Chacho, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-739-7453 | |
Dr. Gunjan Gupta, MD, PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Department Of Pathology And Laboratory Medicine, Danbury, CT 06810 Phone: 203-739-6471 |